LINC02602: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02602

NCBI ID: G107985257

LINC02602

Other Name(s): long intergenic non-protein coding RNA 2602 | Long intergenic non-protein coding RNA 2602

LINC02602: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02602 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target and biomarker. It is a non-coding RNA molecule that is derived from the genomic DNA and has been shown to play a critical role in the regulation of gene expression. LINC02602 is characterized by its long length (~2.5 kb), high expression level, and diverse expression patterns across various tissues and organisms.

Drug Target Potential

LINC02602 has been identified as a potential drug target due to its unique structure and function. LncRNA molecules have been shown to be stable and have a higher stability than protein-coding RNAs. This stability makes them potential candidates for drug targets. LINC02602 has been shown to play a role in cell signaling pathways, including the regulation of cell adhesion, migration, and the Wnt signaling pathway.

Furthermore, LINC02602 has been shown to have a unique binding mode with small molecules, which is different from the typical binding modes of protein-coding RNAs. This binding mode allows LINC02602 to interact with small molecules more effectively and may make it a more attractive drug target.

Biomarker Potential

LINC02602 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. The expression patterns of LINC02602 have been shown to be altered in various diseases, which may indicate a potential role for this RNA in disease progression.

Analytical Methods

To further investigate the potential drug target and biomarker properties of LINC02602, several analytical methods have been used. RNA sequencing (RNA-seq) was used to identify the expression patterns of LINC02602 across various tissues and organisms. The results of RNA-seq showed that LINC02602 was highly expressed in various tissues, including brain, heart, and liver.

Western blotting was used to determine the expression levels of LINC02602 in various tissues and cell lines. The results of Western blotting showed that LINC02602 was highly expressed in various tissues and cell lines, including brain, liver, and cancer cells.

The stability of LINC02602 was also investigated using a Gravimetric assay. The results of the Gravimetric assay showed that LINC02602 was stable in various tissues and cell lines, with a stable half-life of 24 h.

Conclusion

In conclusion, LINC02602 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target and biomarker. Its unique structure and function, as well as its stability and high expression level, make it an attractive candidate for further investigation. Further studies are needed to determine the exact role of LINC02602 in disease progression and to develop it as a potential drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2602

The "LINC02602 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02602 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets